Erteilung des Status eines Therapiedurchbruchs für Sanbexin-Sublingualtabletten durch die US-amerikanische Food and Drug Administration

Posted on by

NANJING, China, 16. September 2024 /PRNewswire/ — Am 2. September 2024 gab Simcere Pharmaceuticals Group Ltd. (2096.HK) bekannt, dass die Sanbexin-Sublingualtabletten (Edaravone- und Dexborneol-Sublingualtabletten), ein innovatives Medikament gegen Schlaganfall, von der US-amerikanischen…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.